Skip to main content
SpringerLink
Log in

Aggressive lymphoma at ASH 2013: R-CHOP under attack?

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Abstract

Recent clinical data presented at the annual meeting of the American Society of Hematology challenge the predominance of R-CHOP in the first line treatment of diffuse large B cell lymphoma. New therapeutic agents such as lenalidomide and ibrutinib are tested successfully in clinical trials in combination with established therapies. Interesting results from the Austrian non-Hodgkin lymphoma (NHL)-13 trial underline the possible relevance of rituximab maintenance in specific patient subgroups. New data on unfavorable subtypes, such as double hit lymphomas, NHL at risk for central nervous system relapse, and refractory disease with CD30 expression were reported. Finally some promising therapeutic options for the unfavorable subset of extranodal NK/T-cell lymphoma were presented.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Chiappella A, Franceschetti S, Castellino A, et al. Final results of phase II study of Lenalidomide plus Rituximab-CHOP21 in elderly untreated diffuse large B-Cell lymphoma focusing on the analysis of the cell of origin: REAL07 trial of the Fondazione Italiana Linfomi. Blood (ASH annual meeting abstracts). 2013;122:(abstr 850).

  2. Younes A, Flinn I, Berdeja J, et al. Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP): updated results from a phase 1b study in treatment-naïve patients with CD20-positive B-cell Non-Hodgkin’s Lymphoma (NHL). Blood (ASH Annual Meeting Abstracts). 2013;122:(abstr 852).

  3. Jaeger U, Trneny M, Melzer H, et al. Rituximab maintenance significantly prolongs Event Free (EFS) and Progression Free Survival (PFS) In male patients with aggressive B-Cell lymphoma in the NHL13 Study. Blood (ASH annual meeting abstracts). 2013;122:(abstr 851).

  4. Jaeger U, Fridrik M, Zeitlinger M, et al. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Haematologica. 2012;97(9):1431–8.

    Google Scholar 

  5. Crump M, Leppae S, Fayad L, et al. A phase III study of Enzastaurin in patients with high-risk diffuse large B cell lymphoma following response to primary treatment, Prelude trial. Blood (ASH annual meeting abstracts). 2013;122:(abstr 371).

  6. Leppae S, Tierens AM, Jorgensen J, et al. Dose-Dense chemoimmunotherapy and early central nervous system prophylaxis for high-risk diffuse large B-Cell lymphoma. –preliminary results from a Nordic phase II study. Blood (ASH annual meeting abstracts). 2013;122:(abstr 849).

  7. Gandhi M, Petrich A, Cassaday R, et al. Impact of induction regimen and consolidative stem cell transplantation in patients with Double Hit Lymphoma (DHL): a large multicenter retrospective analysis. Blood (ASH annual meeting abstracts). 2013;122:(abstr 640).

  8. Xu-Monette Z, Dabaja B, Tzankov A, et al. Radiation therapy significantly improves survival of patients with diffuse large B-Cell lymphoma associated with MYC translocation: a report from the International DLBCL rituximab-CHOP consortium program. Blood (ASH annual meeting abstracts). 2013;122:(abstr 641).

  9. Bartlett N, Sharman J, Oki Y, et al. A phase 2 study of Brentuximab Vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas: interim results in patients with DLBCL and other B-Cell lymphomas. Blood (ASH annual meeting abstracts). 2013;122:(abstr 848).

  10. Gao Y, Huang H, QiChun C, et al. Efficacy and safety of pegaspargase with Gemcitabine and Oxaliplatin in patients with treatment-naïve, refractory extranodal natural killer/T-Cell lymphoma: a single-centre experience. Blood (ASH annual meeting abstracts). 2013;122:(abstr 642).

  11. Yamaguchi M, Tobinai K, Oguchi M, et al. Phase I/II study on concurrent chemoradiotherapy for localized nasal NK/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG2011. J Clin Oncol. 2009;27:5594–600.

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that there are no actual or potential conflicts of interest in relation to this article.

Author information

Authors and Affiliations

  1. 3rd Medical Department for Hematology and Oncology, Hanusch Krankenhaus, Heinrich Collinstrasse 30, 1140, Vienna, Austria

    Thomas Nösslinger MD

Authors
  1. Thomas Nösslinger MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Nösslinger MD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nösslinger, T. Aggressive lymphoma at ASH 2013: R-CHOP under attack?. memo 7, 130–133 (2014). https://doi.org/10.1007/s12254-014-0148-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-014-0148-6

Keywords

Search

Navigation